Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

QUALITY OF LIFE IN A RANDOMIZED BREAST CANCER PREVENTION TRIAL OF LOW-DOSE TAMOXIFEN AND FENRETINIDE IN PREMENOPAUSAL WOMEN.

Serrano D, Gandini S, Guerrieri-Gonzaga A, Feroce I, Johansson H, Macis D, Aristarco V, Bonanni B, DeCensi A.

Cancer Prev Res (Phila). 2018 Oct 23. pii: canprevres.0073.2018. doi: 10.1158/1940-6207.CAPR-18-0073. [Epub ahead of print]

PMID:
30352838
2.

Worry and risk perception of breast cancer in a prevention trial of low dose tamoxifen in midlife postmenopausal hormone users.

Rondanina G, Puntoni M, Guerrieri-Gonzaga A, Marra D, Bonanni B, DeCensi A.

Breast. 2017 Aug;34:108-114. doi: 10.1016/j.breast.2017.05.008. Epub 2017 May 29.

PMID:
28570956
3.

The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.

Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, Curigliano G, Zurrida S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G.

Ann Oncol. 2017 Feb 1;28(2):321-328. doi: 10.1093/annonc/mdw623.

PMID:
28426105
4.

A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2017 Jun;10(6):363-370. doi: 10.1158/1940-6207.CAPR-16-0298. Epub 2017 Apr 11.

5.

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.

Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.

Breast Cancer Res Treat. 2016 Aug;159(1):97-108. doi: 10.1007/s10549-016-3932-7. Epub 2016 Aug 2.

PMID:
27484880
6.

Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS.

Guerrieri-Gonzaga A, Sestak I, Lazzeroni M, Serrano D, Rotmensz N, Cazzaniga M, Varricchio C, Pruneri G, Leonardi MC, Orecchia R, Galimberti V, Bonanni B, DeCensi A.

Int J Cancer. 2016 Nov 1;139(9):2127-34. doi: 10.1002/ijc.30254. Epub 2016 Jul 19.

7.

A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.

Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, Toesca A, Caldarella P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 May;9(5):349-56. doi: 10.1158/1940-6207.CAPR-15-0311. Epub 2016 Feb 29.

8.

Chemoprevention studies within lung cancer screening programmes.

Veronesi G, Guerrieri-Gonzaga A, Infante M, Bonanni B.

Ecancermedicalscience. 2015 Nov 24;9:597. doi: 10.3332/ecancer.2015.597. eCollection 2015. Review.

9.

A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Puccio A, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 Jan;9(1):89-95. doi: 10.1158/1940-6207.CAPR-15-0123. Epub 2015 Nov 2.

10.

Effect of Metformin on Breast Ductal Carcinoma In Situ Proliferation in a Randomized Presurgical Trial.

DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Lazzeroni M, Vingiani A, Gentilini O, Petrera M, Viale G, Cuzick J, Bonanni B, Pruneri G.

Cancer Prev Res (Phila). 2015 Oct;8(10):888-94. doi: 10.1158/1940-6207.CAPR-15-0048. Epub 2015 Aug 14.

11.

Difficult choices for young patients with cancer: the supportive role of decisional counseling.

Chiavari L, Gandini S, Feroce I, Guerrieri-Gonzaga A, Russell-Edu W, Bonanni B, Peccatori FA.

Support Care Cancer. 2015 Dec;23(12):3555-62. doi: 10.1007/s00520-015-2726-5. Epub 2015 Apr 11.

PMID:
25862346
12.

Long-term effects of inhaled budesonide on screening-detected lung nodules.

Veronesi G, Lazzeroni M, Szabo E, Brown PH, DeCensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Grimaldi MC, Spaggiari L, Bonanni B.

Ann Oncol. 2015 May;26(5):1025-30. doi: 10.1093/annonc/mdv064. Epub 2015 Feb 11.

13.

Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.

Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G.

Ann Oncol. 2015 Apr;26(4):682-7. doi: 10.1093/annonc/mdv013. Epub 2015 Jan 18.

PMID:
25600567
14.

Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence.

Toesca A, Botteri E, Lazzeroni M, Vila J, Manika A, Ballardini B, Bettarini F, Guerrieri-Gonzaga A, Bonanni B, Rotmensz N, Viale G, Veronesi P, Luini A, Veronesi U, Gentilini O.

Breast. 2014 Dec;23(6):829-35. doi: 10.1016/j.breast.2014.08.016. Epub 2014 Sep 26.

PMID:
25261930
15.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.

Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25.

16.

Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis.

Macis D, Guerrieri-Gonzaga A, Gandini S.

Int J Epidemiol. 2014 Aug;43(4):1226-36. doi: 10.1093/ije/dyu088. Epub 2014 Apr 15. Review.

17.

Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.

Decensi A, Sun Z, Guerrieri-Gonzaga A, Thürlimann B, McIntosh C, Tondini C, Monnier A, Campone M, Debled M, Schönenberger A, Zaman K, Johansson H, Price KN, Gelber RD, Goldhirsch A, Coates AS, Aebi S.

Breast Cancer Res Treat. 2014 Apr;144(2):321-9. doi: 10.1007/s10549-014-2849-2. Epub 2014 Feb 1.

18.

Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials.

Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A.

Ann Oncol. 2014 Mar;25(3):618-23. doi: 10.1093/annonc/mdt528. Epub 2013 Dec 18.

19.

Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.

Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Macis D, Puccio A, Sandri MT, Gulisano M, Formelli F, Decensi A.

Breast Cancer Res Treat. 2013 Dec;142(3):569-78. doi: 10.1007/s10549-013-2768-7. Epub 2013 Nov 17.

PMID:
24241787
20.

The effect of metformin on apoptosis in a breast cancer presurgical trial.

Cazzaniga M, DeCensi A, Pruneri G, Puntoni M, Bottiglieri L, Varricchio C, Guerrieri-Gonzaga A, Gentilini OD, Pagani G, Dell'Orto P, Lazzeroni M, Serrano D, Viale G, Bonanni B.

Br J Cancer. 2013 Nov 26;109(11):2792-7. doi: 10.1038/bjc.2013.657. Epub 2013 Oct 24.

21.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B.

Breast Cancer Res. 2013 Jun 20;15(3):R47. doi: 10.1186/bcr3439.

22.

Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype.

Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, Varricchio C, Disalvatore D, Del Castillo A, Bassi F, Pagani G, DeCensi A, Viale G, Bonanni B, Pruneri G.

Br J Cancer. 2013 Apr 30;108(8):1593-601. doi: 10.1038/bjc.2013.147. Epub 2013 Apr 11.

23.

Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study.

Guerrieri-Gonzaga A, Lazzeroni M, Botteri E, Serrano D, Rotmensz N, Varricchio MC, Cazzaniga M, Bollani G, Mora S, Montefrancesco C, Pruneri G, Viale G, Intra M, Galimberti V, Goldhirsch A, Bagnardi V, Bonanni B, DeCensi A.

Ann Oncol. 2013 Jul;24(7):1859-66. doi: 10.1093/annonc/mdt113. Epub 2013 Mar 26.

PMID:
23532115
24.

Metformin and breast cancer risk.

Gandini S, Guerrieri-Gonzaga A, Puntoni M, Decensi A.

J Clin Oncol. 2013 Mar 1;31(7):973-4. doi: 10.1200/JCO.2012.46.3596. Epub 2013 Jan 28. No abstract available.

PMID:
23358989
25.

Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo.

Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Casadio C, Jemos C, Pizzamiglio M, Cortesi L, Radice D, Bonanni B.

BMC Cancer. 2012 Dec 5;12:575. doi: 10.1186/1471-2407-12-575.

26.

Vitamin D and overall mortality.

Guerrieri-Gonzaga A, Gandini S.

Pigment Cell Melanoma Res. 2013 Jan;26(1):16-28. doi: 10.1111/pcmr.12036. Epub 2012 Nov 12.

PMID:
23045997
27.

Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial.

Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A.

J Clin Oncol. 2012 Jul 20;30(21):2593-600. doi: 10.1200/JCO.2011.39.3769. Epub 2012 May 7.

PMID:
22564993
28.

Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.

Gjerde J, Gandini S, Guerrieri-Gonzaga A, Haugan Moi LL, Aristarco V, Mellgren G, Decensi A, Lien EA.

Breast Cancer Res Treat. 2012 Jul;134(2):693-700. doi: 10.1007/s10549-012-2074-9. Epub 2012 May 5.

29.

Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?

Cazzaniga M, Varricchio C, Montefrancesco C, Feroce I, Guerrieri-Gonzaga A.

J Biomed Biotechnol. 2012;2012:172897. doi: 10.1155/2012/172897. Epub 2012 Mar 5. Review.

30.

Estrogen receptor in breast ductal carcinoma in situ: good cop, bad cop?

DeCensi A, Pruneri G, Guerrieri-Gonzaga A.

J Clin Oncol. 2012 Apr 20;30(12):1384-6. doi: 10.1200/JCO.2011.40.7494. Epub 2012 Mar 5. Review. No abstract available.

PMID:
22393083
31.

Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, Feroce I, Pizzamiglio M, Sandri MT, Gulisano M, Bonanni B, Decensi A.

J Clin Oncol. 2012 Jan 10;30(2):151-7. doi: 10.1200/JCO.2011.35.2237. Epub 2011 Dec 12.

32.

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B.

Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9. doi: 10.1158/1940-6207.CAPR-10-0337. Epub 2011 Jun 17.

33.

Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.

Veronesi G, Szabo E, Decensi A, Guerrieri-Gonzaga A, Bellomi M, Radice D, Ferretti S, Pelosi G, Lazzeroni M, Serrano D, Lippman SM, Spaggiari L, Nardi-Pantoli A, Harari S, Varricchio C, Bonanni B.

Cancer Prev Res (Phila). 2011 Jan;4(1):34-42. doi: 10.1158/1940-6207.CAPR-10-0182. Epub 2010 Dec 16.

34.

Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology.

Lazzeroni M, Guerrieri-Gonzaga A, Serrano D, Varricchio MC, Veronesi G, Radice D, Feroce I, Nardi-Pantoli A, Lippman SM, Szabo E, Bonanni B.

Contemp Clin Trials. 2010 Nov;31(6):612-9. doi: 10.1016/j.cct.2010.08.006. Epub 2010 Aug 16.

35.

Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer.

DeCensi A, Guerrieri-Gonzaga A, Gandini S, Serrano D, Cazzaniga M, Mora S, Johansson H, Lien EA, Pruneri G, Viale G, Bonanni B.

Ann Oncol. 2011 Mar;22(3):582-7. doi: 10.1093/annonc/mdq427. Epub 2010 Aug 17.

PMID:
20716629
36.

Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.

Haugan Moi LL, Hauglid Flågeng M, Gandini S, Guerrieri-Gonzaga A, Bonanni B, Lazzeroni M, Gjerde J, Lien EA, DeCensi A, Mellgren G.

Clin Cancer Res. 2010 Apr 1;16(7):2176-86. doi: 10.1158/1078-0432.CCR-09-1859. Epub 2010 Mar 23. Erratum in: Clin Cancer Res. 2010 Oct 15;16(20):5087. De Censi, Andrea [corrected to DeCensi, Andrea].

37.

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.

Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B.

Pharmacogenomics J. 2011 Apr;11(2):100-7. doi: 10.1038/tpj.2010.17. Epub 2010 Mar 23.

PMID:
20309015
38.

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.

Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A.

Clin Cancer Res. 2009 Nov 15;15(22):7053-60. doi: 10.1158/1078-0432.CCR-09-1354. Epub 2009 Nov 3.

39.

Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.

Guerrieri-Gonzaga A, Botteri E, Lazzeroni M, Rotmensz N, Goldhirsch A, Varricchio C, Serrano D, Cazzaniga M, Bassi F, Luini A, Bagnardi V, Viale G, Mora S, Bollani G, Albertazzi E, Bonanni B, Decensi A.

Ann Oncol. 2010 May;21(5):949-54. doi: 10.1093/annonc/mdp408. Epub 2009 Oct 25.

PMID:
19858087
40.

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, Gulisano M, Johansson H, Galimberti V, Cassano E, Moroni SM, Formelli F, Lien EA, Pelosi G, Johnson KA, Bonanni B.

J Clin Oncol. 2009 Aug 10;27(23):3749-56. doi: 10.1200/JCO.2008.19.3797. Epub 2009 Jul 13.

41.

Ductal intraepithelial neoplasia: postsurgical outcome for 1,267 women cared for in one single institution over 10 years.

Guerrieri-Gonzaga A, Botteri E, Rotmensz N, Bassi F, Intra M, Serrano D, Renne G, Luini A, Cazzaniga M, Goldhirsch A, Colleoni M, Viale G, Ivaldi G, Bagnardi V, Lazzeroni M, Decensi A, Veronesi U, Bonanni B.

Oncologist. 2009 Mar;14(3):201-12. doi: 10.1634/theoncologist.2008-0203. Epub 2009 Mar 5.

42.

Is it time to test metformin in breast cancer clinical trials?

Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):701-5. doi: 10.1158/1055-9965.EPI-08-0871. Epub 2009 Feb 24.

43.

Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.

Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, Gulisano M, Magni P, Formelli F, Decensi A.

Cancer Res. 2008 Nov 15;68(22):9512-8. doi: 10.1158/0008-5472.CAN-08-0553.

44.

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Lazzeroni M, Macis D, Decensi A, Gandini S, Sandri MT, Serrano D, Guerrieri-Gonzaga A, Johansson H, Mora S, Daldoss C, Omodei U, Bonanni B.

Ecancermedicalscience. 2008;2:67. doi: 10.3332/ecancer.2008.67. Epub 2008 Feb 6.

45.

Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users.

Serrano D, Gandini S, Mariani L, Bonanni B, Santinelli A, Guerrieri-Gonzaga A, Pelosi G, Cassano E, Montironi R, Decensi A.

Breast. 2008 Feb;17(1):91-7. Epub 2007 Sep 4.

PMID:
17768053
46.

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F, Pelosi G, Daldoss C, Omodei U, Johansson H, Macis D, Lazzeroni M, Penotti M, Sironi L, Moroni S, Bianco V, Rondanina G, Gjerde J, Guerrieri-Gonzaga A, Bonanni B.

J Clin Oncol. 2007 Sep 20;25(27):4201-9. Epub 2007 Aug 20.

PMID:
17709798
47.

Relationships between circulating hormone levels, mammographic percent density and breast cancer risk factors in postmenopausal women.

Johansson H, Gandini S, Bonanni B, Mariette F, Guerrieri-Gonzaga A, Serrano D, Cassano E, Ramazzotto F, Baglietto L, Sandri MT, Decensi A.

Breast Cancer Res Treat. 2008 Mar;108(1):57-67. Epub 2007 Apr 28.

PMID:
17468953
48.

A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.

Colombo N, Formelli F, Cantù MG, Parma G, Gasco M, Argusti A, Santinelli A, Montironi R, Cavadini E, Baglietto L, Guerrieri-Gonzaga A, Viale G, Decensi A.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1914-9.

49.

Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.

Johansson H, Bonanni B, Mariette F, Cazzaniga M, Baglietto L, Guerrieri-Gonzaga A, Sandri MT, Luini A, Pelosi G, Decensi A.

Breast Cancer Res Treat. 2006 Jul;98(2):167-72. Epub 2006 Mar 15.

PMID:
16538534
50.

Quality of life assessment in a chemoprevention trial: fenretinide and oral or transdermal HRT.

Serrano D, Mariani L, Mora S, Guerrieri-Gonzaga A, Cazzaniga M, Daldoss C, Ramazzotto F, Feroce I, Decensi A, Bonanni B.

Maturitas. 2006 Aug 20;55(1):69-75. Epub 2006 Feb 24.

PMID:
16500052

Supplemental Content

Loading ...
Support Center